CEA-Scan^® Product Description

CEA-Scan (arcitumomab) is a nuclear imaging agent that in conjunction with standard diagnostic evaluations, detects the presence, location and extent of metastatic disease in patients with primary or recurrent colorectal cancer. Multicenter studies published in peer-reviewed journals (Annals of Surgery, Journal of Clinical Oncology, etc.) demonstrate that adding CEA-Scan to a standard preoperative workup can help identify those patients who will benefit from aggressive procedures, and those for whom minimal surgery and adjuvant chemotherapy would be indicated.

CEA-Scan uses technetium-99m, an inexpensive, readily available isotope available in almost every nuclear medicine department. Since its approval in 1996, CEA-Scan has been used in Europe and the United States to help find cancer that CT alone has missed.

Any professional information can be requested and questions can be directed to 1-888-610-0011.

CEA-Scan + CT provides superior guidance for a more curative resection, compared to CT alone

Virtually nonimmunogenic: <1% of patients experience a HAMA(human anti-mouse antibody) response.

CEA-Scan is a monoclonal antibody that has been fragmented, which not only allows it to tightly bind to technetium, but most importantly reduces the chances of a HAMA response to less than 1%.  This fragment carries technetium-99m to the source of CEA, at the tumor(s), allowing CEA-Scan to identify cancerous lesions.

CEA-Scan has proven in multicenter pivotal trials to be more sensitive than CT or blood CEA studies in the detection and evaluation of metastatic and recurrent colorectal cancer.  When used in addition to Computed Tomography(CT), CEA-Scan has increased the preoperative identification of resectable patients by 40%, and identified twice as many non-resectable patients as CT alone.  CEA-Scan is fully reimbursed by Medicare as well as most HMO's.

click here for Colorectal Cancer Diagnosis, Staging & Monitoring